Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

NRG's Stock Is a Top Gainer. How Does It Really Make Money? The company looks more like a risky energy trader than a simple power producer. Ethan Allen Faces Fewer Tariffs Than Rivals, but Consumer ...

The agreement unites two brands that are popular with Gen Z and helps the buyer diversify its supply chain outside of China. Pipeline operator Williams will seek to build two natural-gas supply lines ...

Eli Lilly acquires SiteOne Therapeutics for up to $1B, signaling potential uptick in Big Pharma deals and focus on non-opioid ...

Chief executive of the Development Bank of Wales, Giles Thorley, reflects on its investment activity nearly eight years since ...

The newest member of the Greenwood Community School Board is looking forward to serving her community in a new way.

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.

Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Smile Group hires a former AstraZeneca executive to spearhead its new HealthTech venture studio, aiming to drive innovation ...

Smile Group enters Healthtech sector with a new venture builder led by Gagandeep Singh Bedi, aiming to scale startups and ...